Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...
Le Lézard

Update on FDA Priority Review of LEQEMBI® IQLIKtm (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...

BioArctic: Leqembi Iqlik PDUFA date updated to August 24 in the U.S.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...
Hosted on MSN

Rare genetic variant inspires new Alzheimer’s plaque-clearing strategy

Unusual resilience: A Colombian man with a mutation for early-onset Alzheimer’s stayed symptom-free for decades longer due to a rare reelin gene variant. Plaque-clearing potential: Research suggests ...